FORTIS · NSE
Fortis Healthcare Limited
₹825
+1.87% (+₹15.15)
Prev. close
₹809.85
Volume
22,88,213
Delivery %
35.3%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “HSBC sets a target price of ₹1,200 for Fortis Healthcare, implying a 30% upside, as the hospital chain enters a new grow…” | HSBC AnalysisHSBC | Fortis Healthcare | PENDING | |
| “Rajani is bullish on Fortis Healthcare, identifying ₹950 as an ideal entry point for a move towards a target of ₹980. Th…” | Vinay RajaniHDFC Securities | Fortis Healthcare Limited | HIT | |
| “Bearish on Fortis Healthcare for the short term (1-2 weeks), recommending a sell at ₹859 with a target of ₹820 and a sto…” | Nagaraj ShettiHDFC Securities | Fortis Healthcare Ltd | MISS | |
| “Recommends buying Fortis Healthcare Ltd above ₹877 with a stop loss at ₹865 and an intraday target of ₹897, based on cur…” | Raja VenkatramanNeoTrader | Fortis Healthcare Ltd | HIT | |
| “Recommends buying Fortis Healthcare for intraday trading at ₹862, with a target of ₹900 and a stop loss at ₹850.” | Vaishali ParekhPrabhudas Lilladher | Fortis Healthcare | HIT | |
| “Recommends buying Fortis Healthcare for intraday trading at ₹865, with a target of ₹885 and a stop loss at ₹855.” | Vaishali ParekhPrabhudas Lilladher | Fortis Healthcare | HIT | |
| “Recommends buying Fortis Healthcare at ₹916, targeting ₹960, with a stop loss at ₹905. This is a short-term trade call f…” | Vaishali ParekhPrabhudas Lilladher | Fortis Healthcare | MISS | |
| “Recommends buying Fortis Healthcare with a target price of ₹1150. The call implies a bullish outlook on the stock.” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Fortis Healthcare | MISS | |
| “Recommends buying Fortis Healthcare in the range of ₹1020-1030, setting a stop loss at ₹980 and a target price of ₹1090.…” | Ganesh DongreAnand Rathi | Fortis Healthcare | MISS | |
| “Bullish on Fortis Healthcare for intraday trading, recommending a buy above ₹1100 with a target of ₹1135 and a stop loss…” | Raja VenkatramanNeoTrader | Fortis Healthcare | NOT TRIGGERED | |
| “Bullish on Fortis Healthcare for 9 October, recommending a buy at ₹1,055.35 with a target of ₹1,095 and a stop loss at ₹…” | Ankush BajajIndependent | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare, suggesting to go long above ₹990 or on dips to ₹955, targeting ₹1,090-1,125 within 1 month…” | Raja VenkatramanNeoTrader | Fortis Healthcare | HIT | |
| “Recommends buying Fortis Healthcare Ltd above ₹990 or on dips to ₹955, with a stop loss at ₹940 and targets between ₹1,0…” | Raja VenkatramanNeoTrader | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare, recommending a buy at ₹970 with a target of ₹1040 and a stop loss at ₹935.” | Sumeet BagadiaChoice Equity Broking | Fortis Healthcare | NOT TRIGGERED | |
| “Short-term traders should consider buying Fortis Healthcare, either immediately or on dips, targeting ₹1,050 within the …” | ETMarkets AnalysisETMarkets.com | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare, suggesting short-term traders consider buying the stock for a target of ₹1,045 in the next…” | ETMarkets AnalysisETMarkets.com | Fortis Healthcare | MISS | |
| “Bullish on Fortis Healthcare Ltd, recommending a buy at ₹920.65 with a target of ₹955 and a stop loss at ₹904 for August…” | Ankush BajajIndependent | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare, recommending a buy at ₹897.35 with a target of ₹960 and a stop loss at ₹865. This stock is…” | Sumeet BagadiaChoice Equity Broking | Fortis Healthcare | NOT TRIGGERED | |
| “Recommends buying Fortis Healthcare with a target price of ₹1000. The call implies a bullish outlook on the stock.” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Fortis Healthcare | HIT | |
| “Bullish on Fortis Healthcare, recommending a buy at ₹884 with a target of ₹909 and a stop loss at ₹868. The stock shows …” | Ankush BajajIndependent | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare Ltd, recommending a buy at ₹850.60 with a near-term target of ₹880–₹890 and a stop loss at …” | Ankush BajajIndependent | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare Ltd, recommending a buy at ₹845.55 with a near-term target of ₹870. The stock shows strong …” | Ankush BajajIndependent | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare Ltd, recommending a buy around ₹846.55 with a target price of ₹906 and a stop loss at ₹817.…” | Sumeet BagadiaChoice Equity Broking | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare, recommending to buy above ₹800 and on dips to ₹780, with a stop loss at ₹770 and a target …” | Raja VenkatramanNeoTrader | Fortis Healthcare Ltd | HIT | |
| “Recommends buying Fortis Healthcare at ₹786, targeting ₹810, with a stop loss at ₹770.” | Vaishali ParekhPrabhudas Lilladher | Fortis Healthcare | HIT | |
| “Prabhudas Lilladher recommends buying Fortis Healthcare with a target price of ₹785.” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Fortis Healthcare | PENDING | |
| “Recommends buying Fortis Healthcare Ltd at ₹692 with a target price of ₹845 in three months and a stop loss at ₹625, bas…” | Marketsmith India AnalysisMarketsmith India | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare Ltd, recommending a buy at ₹687 with a target price of ₹845 in three months and a stop loss…” | Marketsmith India AnalysisMarketsmith India | Fortis Healthcare Ltd | HIT | |
| “Bullish on Fortis Healthcare, recommending a buy at ₹698.35 with a target of ₹744 and a stop loss at ₹671. This call is …” | Sumeet BagadiaChoice Equity Broking | Fortis Healthcare | MISS | |
| “Recommends buying Fortis Healthcare at ₹833.15, setting a stop loss at ₹710 for a target price range of ₹1020-1150. The …” | Kunal KambleBonanza Portfolio | Fortis Healthcare Ltd | PENDING | |
| “Recommends buying Fortis Healthcare shares at ₹671.80, setting a stop loss at ₹648 and targeting ₹719. The stock exhibit…” | Sumeet BagadiaChoice Equity Broking | Fortis Healthcare Ltd | MISS | |
| “Axis Securities has a 'buy' call on Fortis Healthcare with a target price of Rs 693, implying a 10% upside from the curr…” | Axis Securities AnalysisAxis Securities | Fortis Healthcare | PENDING | |
| “Bullish on FORTIS, recommending a buy at ₹608 with targets between ₹650-660 and a stop loss at ₹588. The stock is tradin…” | Ankush BajajIndependent | Fortis Healthcare Ltd | HIT | |
| “Recommends buying Fortis at ₹608 with targets of ₹650-660 and a stop loss at ₹588. The stock is in oversold territory, f…” | Ankush BajajIndependent | Fortis Healthcare Ltd | HIT | |
| “Prabhudas Lilladher recommends buying Fortis Healthcare with a target price of ₹760. The call implies a bullish outlook …” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Fortis Healthcare | PENDING | |
| “Recommends buying Fortis Healthcare at ₹654 with a positional target price of ₹680-700 and a stop loss of ₹630.” | Vaishali ParekhPrabhudas Lilladher | Fortis Healthcare | MISS | |
| “Bullish on Fortis Healthcare, setting a target of 860 from a CMP of 672, indicating a 28% upside. This recommendation is…” | Axis Securities AnalysisAxis Securities | Fortis Healthcare Ltd | HIT | |
| “Prabhudas Lilladher recommends buying Fortis Healthcare with a target price of ₹710. The call implies a bullish outlook …” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Fortis Healthcare | PENDING |
Long-Horizon calls · 1yr+ horizon · verdict pending
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends 'buy' on Fortis Healthcare, targeting ₹775, as the hospital sector shows strong growth trajectory backed by s…” | Axis Securities AnalysisAxis Securities | Fortis Healthcare | PENDING |
Market commentary · 8 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Fortis Healthcare, expecting 16.8% YoY revenue growth in Q2FY26, led by increased contribution from core spec…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Fortis Healthcare Ltd | — | |
| “Bullish on Fortis Healthcare Ltd, recommending a buy at ₹845.55 with a near-term target of ₹870. The stock shows strong …” | Ankush BajajIndependent | Fortis Healthcare Ltd | — | |
| “Bullish on Fortis Healthcare Ltd, suggesting a buy in the range of ₹678–702, targeting a profit goal of ₹845 with a stop…” | Marketsmith India AnalysisMarketsmith India | Fortis Healthcare Ltd | — | |
| “Recommends buying Fortis Healthcare Ltd in the range of ₹678–702, targeting a profit goal of ₹845 with a stop loss at ₹6…” | Marketsmith India AnalysisMarketsmith India | Fortis Healthcare Ltd | — | |
| “Bullish on Fortis Healthcare Ltd; recommends buying in the range of ₹625–645 from the current market price of ₹639.1, wi…” | Marketsmith India AnalysisMarketsmith India | Fortis Healthcare Ltd | — | |
| “Recommends buying Fortis Healthcare Limited within the range of ₹625–645, targeting a profit goal of ₹740 with a stop lo…” | Marketsmith India AnalysisMarketsmith India | Fortis Healthcare Limited | — | |
| “Bullish on Fortis Healthcare, reiterating a 'Buy' rating with a 20-30% upside potential over the next 12 months. The pos…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Fortis Healthcare | — | |
| “Expects strong Q2 earnings for hospital companies, with healthy occupancy in the Delhi NCR region due to heavy monsoon. …” | Jefferies AnalysisJefferies | Fortis Healthcare Ltd | — |
Fundamentals
About Fortis Healthcare Limited
Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company services in the areas of cardiac science, nephrology, diabetology/endocrinology, foetal medicine, infectious diseases, mental health and behavioral science, oncology, orthopedics, physiotherapy and rehabilitation, rheumatology, urology, nuclear medicine, critical care, emergency and trauma, general surgery, internal medicine, neurointerventional radiology, obstetrics and gynaecology, pediatrics, pediatrics, vascular surgery, and support facilities. It also provides services in the areas of infertility medicine, dental science, endocrine surgery, geriatric medicine, liver transplant and hepatobiliary sciences, neurology, ophthalmology, pain and palliative medicine, pulmonology, thoracic surgery, gastroenterology sciences, dermatology, ENT, haematology, medical generics, neurology, organ transplant, radiology, and transfusion medicines. In addition, the company offers various spectrum integrated healthcare services ranging from clinics to quaternary care facilities and a range of ancillary services, as well as secondary, and tertiary care services. The company's healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. Fortis Healthcare Limited was incorporated in 1996 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Ashutosh Raghuvanshi
Headquarters
Gurugram
Employees
14,649
Website
fortishealthcare.comExchange
View on NSE ↗Key stats
Market cap
₹59,445.41 Cr
P/E ratio (TTM)
56.7
Dividend yield
0.13%
EPS (TTM)
₹13.88
Beta (1Y · daily vs NIFTY 50)
0.74
Beta (5Y · monthly vs NIFTY 50)
1.41
Shares float
48.93 Cr
EPS · quarter ended Jun 2026
₹3.53
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹4,030.12 Cr | ₹5,717.61 Cr | ₹6,297.63 Cr | ₹6,892.92 Cr | ₹7,782.75 Cr | ₹9,127.84 Cr | |
EBITDA | ₹452.21 Cr | ₹1,411.33 Cr | ₹1,237.80 Cr | ₹1,308.51 Cr | ₹1,547.49 Cr | ₹2,097.86 Cr |
| ₹-109.76 Cr | ₹555.12 Cr | ₹588.73 Cr | ₹598.88 Cr | ₹774.21 Cr | ₹1,041.78 Cr | |
Diluted EPS | ₹-1.45 | ₹7.35 | ₹7.8 | ₹7.93 | ₹10.26 | ₹13.8 |
Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹-109.76 Cr while the annual report gives ₹-56.17 Cr (48.8% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹91.49 Cr) is left blank here too, rather than shown from only one of the two sources.
EBITDA for Mar 2022 could not be checked against the company's own annual report: this page shows ₹1,411.33 Cr while the annual report gives ₹1,096.30 Cr (22.3% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹662.16 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹10,866.00 Cr | ₹11,516.00 Cr | ₹12,089.00 Cr | ₹12,971.00 Cr | ₹13,377.00 Cr | ₹15,833.00 Cr | |
| ₹1,530.55 Cr | ₹1,254.93 Cr | ₹925.72 Cr | ₹1,155.02 Cr | ₹2,475.11 Cr | ₹3,472.58 Cr | |
Stockholders' equity | ₹6,120.00 Cr | ₹6,178.00 Cr | ₹7,242.00 Cr | ₹7,663.00 Cr | ₹8,917.00 Cr | ₹9,896.00 Cr |
Trade receivables, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹485.00 Cr | ₹865.00 Cr | ₹822.00 Cr | ₹1,100.00 Cr | ₹1,424.00 Cr | ₹1,601.00 Cr | |
Investing cash flow | ₹-135.11 Cr | ₹-514.38 Cr | ₹-373.70 Cr | ₹-886.35 Cr | ₹-779.38 Cr | ₹-1,538.41 Cr |
| ₹-143.00 Cr | ₹-517.00 Cr | ₹-471.00 Cr | ₹-86.00 Cr | ₹-714.00 Cr | ₹164.00 Cr | |
Capital expenditure | ₹-218.51 Cr | ₹-215.49 Cr | ₹-447.24 Cr | ₹-942.47 Cr | ₹-846.94 Cr | ₹-945.53 Cr |
End cash position | — | ₹66.60 Cr | ₹45.14 Cr | ₹169.66 Cr | ₹99.91 Cr | ₹328.32 Cr |
End cash position has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 31.17% |
| Public | 68.83% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Fortis Healthcare Limited | ₹59,445.41 Cr | ₹790.65 | 56.7 | 6.01 | 10.5% | 0.35 | +17.1% | -22.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.